Home › Ovarian Cancer › Louisiana › Baton Rouge
Ovarian Cancer clinical trials in Baton Rouge, LA
3 studies for Ovarian Cancer are looking for participants at sites in and around Baton Rouge (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
RecruitingPhase 2
- Our Lady of the Lake Physician Group - Medical Oncology /ID# 277440, Baton Rouge
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
RecruitingPhase 3
- LSU Health Baton Rouge-North Clinic, Baton Rouge
- Our Lady of the Lake Physician Group, Baton Rouge
- Our Lady of The Lake, Baton Rouge
- and 1 more
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- Our Lady of the Lake, Baton Rouge
About Ovarian Cancer
Ovarian cancer is a cancerous tumor that forms in the tissues of an ovary. The ovaries are a pair of female reproductive glands that make eggs and female hormones.
More about Ovarian Cancer on MedlinePlus
Ovarian Cancer trials in other cities
- Houston, TX89 studies
- New York City, NY69 studies
- Boston, MA61 studies
- Los Angeles, CA50 studies
- Nashville, TN49 studies
- Arlington, VA46 studies
- Philadelphia, PA44 studies
- Columbus, OH39 studies
- St. Louis, MO38 studies
- Chicago, IL36 studies
- San Antonio, TX31 studies
- Cleveland, OH30 studies
Other studies in Baton Rouge
- Obesity15 studies
- Overweight10 studies
- Non-Small Cell Lung Cancer10 studies
- Metastatic Cancer9 studies
- Acute Myeloid Leukemia8 studies
- Lung Cancer8 studies
- Colorectal Cancer8 studies
- Breast Cancer7 studies
- Bladder Cancer6 studies
- Chronic Lymphocytic Leukemia5 studies
- Prostate Cancer5 studies
- COPD5 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.